Open AccessRepSox Slows Decay of CD34 + Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin‐3 Expression
Author(s) -
Jajosky Audrey N.,
Coad James E.,
Vos Jeffrey A.,
Martin Karen H.,
Senft Jamie R.,
Wenger Sharon L.,
Gibson Laura F.
Publication year - 2014
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2013-0193
Subject(s) - cd34 , cancer research , haematopoiesis , stem cell , immune system , immunology , myeloid , biology , progenitor cell , myeloid leukemia , stromal cell , microbiology and biotechnology
To facilitate development of therapies that target leukemic stem/progenitor cells (LPCs), in vitro ways to enhance the survival and immunogenicity of a patient's CD34 + acute myeloid leukemia (AML) cells were explored. RepSox was identified as a candidate cell‐engineering tool because it slows in vitro decay of CD34 + AML cells (which often contain LPCs) and accelerates loss of the immune checkpoint receptor T cell immunoglobulin mucin‐3 (Tim‐3).